Physician profile
Alva Dillon
NPI 1699775171
$4,416.94
in general payments reported to CMS, 2019-2025
27 companies · $713 in 2025
The $713 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $340 · 2021: $927 · 2022: $227 · 2023: $759 · 2024: $752 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,640.66 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $691.12 | 2019-2025 | Xifaxan, Relistor |
| Nestle Healthcare Nutrition INC. | $249.13 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $219.00 | 2019-2021 | |
| Genzyme Corporation | $214.19 | 2023-2025 | |
| Ardelyx, INC. | $158.24 | 2023-2024 | Ibsrela |
| Gilead Sciences, INC. | $147.89 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $139.77 | 2021-2025 | Linzess |
| Medtronic USA, INC. | $123.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $119.01 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $112.15 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $88.71 | 2021-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $86.48 | 2025 | Zenpep, Vowst |
| Qol Medical, LLC | $83.48 | 2019-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $77.16 | 2024 | Vegzelma |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $46.47 | 2023-2024 | Hadlima |
| Pfizer INC. | $41.07 | 2019-2021 | |
| Janssen Biotech, INC. | $37.54 | 2023-2024 | Stelara, Simponi, Remicade |
| Allergan, INC. | $27.45 | 2019 | |
| Novo Nordisk INC | $18.39 | 2025 | Wegovy, Saxenda |
| Ipsen Biopharmaceuticals, INC | $17.00 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $16.49 | 2020 | |
| Merck Sharp & Dohme LLC | $15.03 | 2021 | |
| Daiichi Sankyo INC. | $14.27 | 2022 | |
| Medtronic, INC. | $14.01 | 2023 | Barrx |
| Evoke Pharma, INC. | $12.52 | 2021 | |
| Romark Laboratories, Lc | $6.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alva Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.